Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a slight decline of 0.23% recently, reflecting a mixed performance over different time frames, with a year-to-date decrease of 0.88% [1]. Group 1: Index Performance - The China Securities Index for Healthcare Equipment and Services closed at 13,568.19 points with a trading volume of 15.409 billion yuan [1]. - Over the past month, the index has increased by 2.13%, while it has decreased by 5.63% over the last three months [1]. - The index has a year-to-date decline of 0.88% [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, selected from the broader China Securities Index to reflect the overall performance of healthcare-related securities [1]. - The top ten weighted companies in the index include Mindray Medical (9.73%), Aier Eye Hospital (8.29%), and United Imaging Healthcare (7.73%) [1]. - The index is primarily composed of companies listed on the Shenzhen Stock Exchange (61.00%) and the Shanghai Stock Exchange (39.00%) [1]. Group 3: Fund Tracking - Several public funds track the China Securities Index for Healthcare Equipment and Services, including Southern Asset Management's various funds and Tianhong's ETF [2].

Company Overview - Jiuan Medical closed at 38.6 yuan, up 2.71%, with a rolling PE ratio of 10.82 times and a total market value of 18.263 billion yuan [1] - The company ranks 32nd in the medical device industry, which has an average PE ratio of 49.84 times and a median of 36.59 times [1] - As of the first quarter of 2025, 36 institutions hold shares in Jiuan Medical, including 32 funds, 3 other entities, and 1 social security fund, with a total holding of 174.5256 million shares valued at 7.337 billion yuan [1] Financial Performance - In the first quarter of 2025, Jiuan Medical reported revenue of 507 million yuan, a year-on-year decrease of 33.49% [1] - The net profit for the same period was 266 million yuan, reflecting a year-on-year increase of 7.62% [1] - The sales gross margin stood at 70.46% [1] Industry Context - The medical device industry has a significant average PE ratio of 49.84 times, indicating a high valuation compared to Jiuan Medical's PE ratio [2] - The industry median PE ratio is 36.59 times, further highlighting Jiuan Medical's relatively lower valuation [2]

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a recent increase, reflecting a mixed performance over different time frames [1][2]. Group 1: Index Performance - The China Securities Index for Healthcare Equipment and Services rose by 0.39% to 13,367.74 points, with a trading volume of 14.635 billion yuan [1]. - Over the past month, the index has increased by 5.82%, while it has decreased by 2.05% over the last three months and by 2.72% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, selected from the broader China Securities Index to reflect the overall performance of healthcare-related securities [1]. - The top ten weighted companies in the index include: Mindray Medical (9.57%), Aier Eye Hospital (8.34%), United Imaging (7.63%), Aimeike (3.55%), Huatai Medical (3.28%), Yuyue Medical (2.88%), New Industry (2.81%), Meinian Onehealth (2.35%), Lepu Medical (2.07%), and Jiuan Medical (2.03%) [1]. Group 3: Market Segmentation - The index's holdings are primarily listed on the Shenzhen Stock Exchange (60.66%) and the Shanghai Stock Exchange (39.34%) [1]. - In terms of industry composition, medical devices account for 34.34%, medical consumables for 27.26%, in vitro diagnostics for 21.50%, and medical services for 16.90% [2]. Group 4: Fund Tracking - Several public funds track the China Securities Index for Healthcare Equipment and Services, including Southern China Securities Index Healthcare Equipment and Services Link A, C, and I, Tianhong China Securities Index Healthcare Equipment and Services ETF, and others [2].

证券代码：002432 证券简称：九安医疗 公告编号：2025-042 3.本次行权采用自主行权模式。 4.本次实际可行权期限为 2025 年 5 月 8 日至 2026 年 4 月 30 日止。 天津九安医疗电子股份有限公司 关于2021年股票期权激励计划第三个行权期 采用自主行权模式的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整， 并对公告中的虚假记载、误导性陈述或者重大遗漏承担连带责任。 特别提示： 1.公司本次股票期权代码：037205，期权简称：九安 JLC2。 2.公司 2021 年股票期权激励计划第三个行权期符合行权条件的激励对象共计 296 人，可行权的期权数量为 1,424,250 份，行权价格为 3.14 元/份。 5.本次可行权股票期权若全部行权，公司股份仍具备上市条件。 天津九安医疗电子股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召 开第六届董事会第二十二次会议和第六届监事会第十七次会议审议通过了《关于 2021 年股票期权激励计划第三个行权期行权条件成就的议案》，具体内容详见 公司于 2025 年 4 月 29 日刊登在巨潮资讯网上的《关于 2 ...

证券代码：002432 证券简称：九安医疗 公告编号：2025-041 天津九安医疗电子股份有限公司 关于2021年股票期权激励计划部分已授予股票期权 注销完成的公告 综上所述，公司本次合计注销以上尚未行权的股票期权 289,500 份。公司 2021 年股票期权激励计划的激励对象总数由 316 人调整为 301 人，本次注销后，激励对 象已获授但行权条件尚未成就的股票期权数量由 323 万份调整为 151.75 万份。 具体内容详见 2025 年 4 月 29 日披露 于《证券时报》、巨潮资讯网 （www.cninfo.com.cn）的《关于注销 2021 年股票期权激励计划部分股票期权的公 告》（公告编号：2025-034）。 2025 年 5 月 7 日，经中国证券登记结算有限责任公司深圳分公司审核确认，上 述 289,500 份股票期权的注销事宜已办理完成。本次注销股票期权事项符合《上市公 司股权激励管理办法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市 公司规范运作》《公司章程》及公司《2021 年股票期权激励计划（草案二次修订稿）》 等相关规定,不存在损害公司及其他股东特别是中小股东 ...

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company has demonstrated significant brand channel advantages and is expected to open a second growth curve through its chronic disease O+O model [7] - The company's iHealth brand has gained substantial recognition globally, with products registered in various regions including the Americas, EU, Asia, and Australia [7] - The company is actively expanding its market presence through new retail platforms and e-commerce channels in the domestic market [7] - The O+O model for diabetes care aims to provide comprehensive care services, enhancing treatment efficiency and resource utilization [7] - The financial forecasts for 2025-2027 indicate expected revenues of 28.1 billion, 34.7 billion, and 35.4 billion respectively, with net profits of 14.5 billion, 16.5 billion, and 16.7 billion [7] Financial Summary - Total revenue for 2024 is projected at 25.9 billion, a decrease of 19.77% year-on-year, with a net profit of 16.7 billion, an increase of 33.3% year-on-year [7] - The earnings per share (EPS) for 2024 is estimated at 3.53 yuan, with a price-to-earnings (P/E) ratio of 10.75 [1][8] - The company’s total assets are expected to reach 27.57 billion by 2025, with a debt-to-equity ratio of 18.84% [8]

经济观察网讯 5月6日重点关注的财经要闻与资本市场大事： （原标题：今日看点｜北交所为试点股票启用新证券代码） 5月6日，21家公司共发布21个股票回购相关进展。其中，2家公司首次披露股票回购预案，14家公司披 露股票回购实施进展，5家公司回购方案已实施完毕。 从首次披露回购预案来看，当日共1家公司股票回购预案金额超千万。科思科技、毅昌科技回购预案金 额最高，分别拟回购不超5000.0万元、66.36万元。从回购实施进展来看，美的集团、长春高新、九安医 疗回购金额最高，分别回购5.54亿元、4.0亿元、3.7亿元。从已完成回购来看，当日共4家公司回购金额 超千万。华工科技、天茂集团、万邦德已完成回购金额最高，分别回购3.95亿元、9998.26万元、 5998.85万元。 4、美国3月贸易帐、欧元区3月PPI月率等数据将公布。 （数据来源Wind，内容不构成任何投资建议） 1、北交所为试点股票启用新证券代码 近日，北交所发布通知，北交所存量上市公司代码切换试点工作总体准备就绪，拟于2025年5月6日正式 上线。根据通知，2025年5月1日至2025年5月5日期间，北交所组织开展代码切换与通关测试，自2025年 ...

证券代码：002432 证券简称：九安医疗 公告编号：2025-040 截至2025年4月30日，公司通过股份回购专用证券账户以集中竞价方式累计 回购公司股份数9,629,405股，占公司总股本的2.04%，最高成交价为42.17元/股， 最低成交价为36.38元/股，支付的总金额为人民币369,962,806.12元（不含交易费 用）。本次回购符合相关法律法规的要求，符合既定的回购股份方案。 二、其他说明 公司回购股份的时间、数量、价格及集中竞价交易的委托时间段均符合《深 圳证券交易所上市公司自律监管指引第9号—回购股份》及公司回购股份方案的 相关规定，具体说明如下： 1、公司未在下列期间内回购公司股票： （1）自可能对公司股票交易价格产生重大影响的重大事项发生之日或者在 决策过程中，至依法披露之日内； 天津九安医疗电子股份有限公司 关于回购公司股份比例达到2%暨回购进展的公告 本公司及董事会全体成员保证公告内容真实、准确和完整， 并对公告中的虚假记载、误导性陈述或者重大遗漏承担连带责任。 天津九安医疗电子股份有限公司（以下简称："公司"）于2025年3月26日 召开了第六届董事会第十九次会议，审议并通过了 ...

Summary of the Conference Call for 九安医疗 Company Overview - **Company**: 九安医疗 (Jiuan Medical) - **Industry**: Medical Devices and Healthcare Key Financial Performance - **2024 Profit**: Increased by 33% to 1.668 billion CNY, primarily driven by asset management business [2][3] - **2025 Q1 Revenue**: Decreased by 34.5% to 500 million CNY due to reduced U.S. orders, but profit remained stable at 266 million CNY [2][3] - **Net Assets**: Increased to 21.4 billion CNY by the end of Q1 2025, up approximately 700 million CNY from the previous year [5] Strategic Initiatives - **Production Shift**: Gradually transferring production to Vietnam to meet U.S. market demand, with Mexico being evaluated as an alternative [2][6][7] - **CGM Product Development**: Continuous Glucose Monitoring (CGM) product clinical trials expected to start in May 2025, with a focus on U.S. market approval [2][8] - **AI Integration**: Actively applying AI technology in chronic disease management, aiming to develop a comprehensive home healthcare system [2][9][10] Market Positioning - **U.S. Market Focus**: Prioritizing CGM product approvals in China, the U.S., and Europe, with the U.S. market potential estimated at 5 billion USD annually [2][8] - **Home Testing Products**: Launched a combined testing product for COVID-19, influenza A, and B in the U.S., with plans for more home disease testing products [2][10] Risk Management and Adaptation - **Tariff Impact**: Significant impact from U.S.-China tariffs, leading to inventory strategies and production agreements with Vietnamese factories [2][6] - **Asset Management Strategy**: Diversified asset allocation strategy targeting a minimum annual return of 6%, with fixed income assets comprising 65.2% of the portfolio [4][20] R&D and Future Investments - **R&D Spending**: Expected increase in R&D expenses focused on AI technology, CGM, and AI smart hearing aids [4][12] - **Chronic Disease Management**: Plans to enhance diabetes care services through AI, targeting over 1,000 hospitals [27] Product Development and Market Trends - **AI Smart Hearing Aids**: Currently in development, with expected registration preparations by late 2025 or early 2026 [23][24] - **Respiratory Testing Products**: Continuous demand expected for respiratory testing products, with historical data analysis guiding demand forecasting [4][11] Strategic Partnerships and Collaborations - **Collaboration with Xiaomi**: Ongoing partnership despite Xiaomi's divestment from certain assets, maintaining a focus on new retail and health product launches [21][22] Stock Buyback and Market Confidence - **Stock Buyback Plans**: Significant buyback activity since 2020, with a commitment to continue repurchasing shares to enhance shareholder value [28] Future Outlook - **Strategic Vision**: Focus on leveraging iHealth brand in the U.S. for product expansion, enhancing diabetes care, and investing in innovative technologies [29]

Group 1: Key Points on 可孚医疗 (Cofe Medical) - In 2024, Cofe Medical will deepen its core category strategy, focusing on hearing aids and dressing materials, with some products having a high market share [1] - The medical care and health monitoring segments experienced growth in Q1, while the respiratory support segment declined, with national subsidy policies boosting sales [1] - A new generation of respiratory machines is planned for launch in 2025 to enhance product performance, and AI technology will be applied in dynamic blood glucose meters and blood pressure monitors to improve intelligence [1] - The medical care segment is expected to see an 8% year-on-year revenue growth in 2024, with a focus on cultivating dressing products [1] - The overseas business is in a strategic cultivation phase, with foreign trade revenue increasing in Q1 [1] Group 2: Key Points on 九安医疗 (Jiuan Medical) - Jiuan Medical's core strategy revolves around iHealth products and a new "O+O" model for diabetes care, with projected revenue of 76.16 million yuan in 2024 from diabetes care services [2] - The company has launched various medical health products in both the US and domestic markets, including a tri-test reagent kit and nasal wash [2] - Jiuan Medical is making strategic investments across various asset classes, including fixed income, equity, and hard technology, particularly in AIoT diabetes home assistance and continuous glucose monitoring projects [2] - The company is committed to R&D investments, especially in AI smart hearing aids [2] - Jiuan Medical is enhancing market confidence through stock buybacks and promoting its core strategy to boost employee morale [2]